
Alana Harris Dent
Examiner (ID: 7014)
| Most Active Art Unit | 1643 |
| Art Unit(s) | 1643, 1642 |
| Total Applications | 1512 |
| Issued Applications | 526 |
| Pending Applications | 351 |
| Abandoned Applications | 660 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 10110043
[patent_doc_number] => 09145446
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2015-09-29
[patent_title] => 'Conjugate comprising P21 protein for the treatment of cancer'
[patent_app_type] => utility
[patent_app_number] => 12/608718
[patent_app_country] => US
[patent_app_date] => 2009-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 13
[patent_no_of_words] => 5652
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12608718
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/608718 | Conjugate comprising P21 protein for the treatment of cancer | Oct 28, 2009 | Issued |
Array
(
[id] => 6575366
[patent_doc_number] => 20100047167
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-02-25
[patent_title] => 'COMBINATION THERAPY IN THE TREATMENT OF CANCER'
[patent_app_type] => utility
[patent_app_number] => 12/605491
[patent_app_country] => US
[patent_app_date] => 2009-10-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9129
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0047/20100047167.pdf
[firstpage_image] =>[orig_patent_app_number] => 12605491
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/605491 | COMBINATION THERAPY IN THE TREATMENT OF CANCER | Oct 25, 2009 | Abandoned |
Array
(
[id] => 6477499
[patent_doc_number] => 20100041594
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-02-18
[patent_title] => 'Use of Aplidine for the Treatment of Pancreatic Cancer'
[patent_app_type] => utility
[patent_app_number] => 12/604900
[patent_app_country] => US
[patent_app_date] => 2009-10-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 5040
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0041/20100041594.pdf
[firstpage_image] =>[orig_patent_app_number] => 12604900
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/604900 | Use of Aplidine for the Treatment of Pancreatic Cancer | Oct 22, 2009 | Abandoned |
Array
(
[id] => 6614726
[patent_doc_number] => 20100063747
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-03-11
[patent_title] => 'Using Plasma Proteomic Pattern For Diagnosis, Classification, Prediction of Response to Therapy and Clinical Behavior, Stratification of Therapy, and Monitoring Disease in Hematologic Malignancies'
[patent_app_type] => utility
[patent_app_number] => 12/582998
[patent_app_country] => US
[patent_app_date] => 2009-10-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 19
[patent_figures_cnt] => 19
[patent_no_of_words] => 14081
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0063/20100063747.pdf
[firstpage_image] =>[orig_patent_app_number] => 12582998
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/582998 | Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies | Oct 20, 2009 | Issued |
Array
(
[id] => 7499520
[patent_doc_number] => 20110262471
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-10-27
[patent_title] => 'RAB6KIFL/KIF20A EPITOPE PEPTIDE AND VACCINES CONTAINING THE SAME'
[patent_app_type] => utility
[patent_app_number] => 13/125548
[patent_app_country] => US
[patent_app_date] => 2009-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 17412
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0262/20110262471.pdf
[firstpage_image] =>[orig_patent_app_number] => 13125548
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/125548 | RAB6KIFL/KIF20A epitope peptide and vaccines containing the same | Oct 14, 2009 | Issued |
Array
(
[id] => 7744158
[patent_doc_number] => 20120021937
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-01-26
[patent_title] => 'DETECTION OF CARCINOMA IN SITU IN SEMEN SPECIMENS'
[patent_app_type] => utility
[patent_app_number] => 13/124405
[patent_app_country] => US
[patent_app_date] => 2009-10-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 15133
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 18
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0021/20120021937.pdf
[firstpage_image] =>[orig_patent_app_number] => 13124405
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/124405 | DETECTION OF CARCINOMA IN SITU IN SEMEN SPECIMENS | Oct 7, 2009 | Abandoned |
Array
(
[id] => 6323010
[patent_doc_number] => 20100196891
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-08-05
[patent_title] => 'IBC-1 (Invasive Breast Cancer-1), a Putative Oncogene Amplified in Breast Cancer'
[patent_app_type] => utility
[patent_app_number] => 12/573017
[patent_app_country] => US
[patent_app_date] => 2009-10-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 11998
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0196/20100196891.pdf
[firstpage_image] =>[orig_patent_app_number] => 12573017
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/573017 | IBC-1 (Invasive Breast Cancer-1), a putative oncogene amplified in breast cancer | Oct 1, 2009 | Issued |
Array
(
[id] => 6446956
[patent_doc_number] => 20100105051
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-04-29
[patent_title] => 'COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER'
[patent_app_type] => utility
[patent_app_number] => 12/567205
[patent_app_country] => US
[patent_app_date] => 2009-09-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47619
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0105/20100105051.pdf
[firstpage_image] =>[orig_patent_app_number] => 12567205
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/567205 | COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND THERAPY OF BREAST CANCER | Sep 24, 2009 | Abandoned |
Array
(
[id] => 10505284
[patent_doc_number] => 09233144
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-01-12
[patent_title] => 'Tyrosine kinase receptor TYRO3 as a therapeutic target in the treatment of cancer'
[patent_app_type] => utility
[patent_app_number] => 13/062804
[patent_app_country] => US
[patent_app_date] => 2009-09-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 24
[patent_no_of_words] => 10145
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13062804
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/062804 | Tyrosine kinase receptor TYRO3 as a therapeutic target in the treatment of cancer | Sep 17, 2009 | Issued |
Array
(
[id] => 7574141
[patent_doc_number] => 20110269797
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-11-03
[patent_title] => 'ANLN PROTEIN AS AN ENDOCRINE TREATMENT PREDICTIVE FACTOR'
[patent_app_type] => utility
[patent_app_number] => 13/061436
[patent_app_country] => US
[patent_app_date] => 2009-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 20
[patent_no_of_words] => 31822
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 11
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0269/20110269797.pdf
[firstpage_image] =>[orig_patent_app_number] => 13061436
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/061436 | ANLN PROTEIN AS AN ENDOCRINE TREATMENT PREDICTIVE FACTOR | Aug 31, 2009 | Abandoned |
Array
(
[id] => 5374242
[patent_doc_number] => 20090311803
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-17
[patent_title] => 'Treatment Of Tumors Expressing Mutant EGF Receptors'
[patent_app_type] => utility
[patent_app_number] => 12/544495
[patent_app_country] => US
[patent_app_date] => 2009-08-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 9
[patent_no_of_words] => 13349
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0311/20090311803.pdf
[firstpage_image] =>[orig_patent_app_number] => 12544495
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/544495 | Treatment Of Tumors Expressing Mutant EGF Receptors | Aug 19, 2009 | Abandoned |
Array
(
[id] => 8749276
[patent_doc_number] => 08415107
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-04-09
[patent_title] => 'Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer'
[patent_app_type] => utility
[patent_app_number] => 12/543855
[patent_app_country] => US
[patent_app_date] => 2009-08-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 4
[patent_no_of_words] => 17719
[patent_no_of_claims] => 41
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 219
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12543855
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/543855 | Thrombospondin fragments and binding agents in the detection, diagnosis and evaluation of cancer | Aug 18, 2009 | Issued |
Array
(
[id] => 5552282
[patent_doc_number] => 20090286268
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-19
[patent_title] => 'Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples'
[patent_app_type] => utility
[patent_app_number] => 12/507737
[patent_app_country] => US
[patent_app_date] => 2009-07-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 6
[patent_no_of_words] => 20403
[patent_no_of_claims] => 44
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0286/20090286268.pdf
[firstpage_image] =>[orig_patent_app_number] => 12507737
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/507737 | Assays for Cancer Patient Monitoring Based on Levels of Analyte Components of the Plasminogen Activator System in Body Fluid Samples | Jul 21, 2009 | Abandoned |
Array
(
[id] => 5557774
[patent_doc_number] => 20090269351
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-10-29
[patent_title] => 'METHOD OF DIAGNOSING AND TREATING GLIOMA'
[patent_app_type] => utility
[patent_app_number] => 12/498181
[patent_app_country] => US
[patent_app_date] => 2009-07-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 12
[patent_no_of_words] => 40925
[patent_no_of_claims] => 17
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0269/20090269351.pdf
[firstpage_image] =>[orig_patent_app_number] => 12498181
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/498181 | METHOD OF DIAGNOSING AND TREATING GLIOMA | Jul 5, 2009 | Abandoned |
Array
(
[id] => 9502996
[patent_doc_number] => 08741306
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-06-03
[patent_title] => 'Kidney specific tumor vaccine directed against kidney tumor antigen G-250'
[patent_app_type] => utility
[patent_app_number] => 12/479415
[patent_app_country] => US
[patent_app_date] => 2009-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 22
[patent_no_of_words] => 22668
[patent_no_of_claims] => 21
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 93
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12479415
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/479415 | Kidney specific tumor vaccine directed against kidney tumor antigen G-250 | Jun 4, 2009 | Issued |
Array
(
[id] => 8265840
[patent_doc_number] => 20120165268
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2012-06-28
[patent_title] => 'P53 FUSION PROTEINS AND METHODS OF MAKING AND USING THEREOF'
[patent_app_type] => utility
[patent_app_number] => 13/321805
[patent_app_country] => US
[patent_app_date] => 2009-05-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 14100
[patent_no_of_claims] => 37
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13321805
[rel_patent_id] =>[rel_patent_doc_number] =>) 13/321805 | P53 FUSION PROTEINS AND METHODS OF MAKING AND USING THEREOF | May 27, 2009 | Abandoned |
Array
(
[id] => 6396267
[patent_doc_number] => 20100304409
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-12-02
[patent_title] => 'METHOD FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS AND A KIT FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS'
[patent_app_type] => utility
[patent_app_number] => 12/472135
[patent_app_country] => US
[patent_app_date] => 2009-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 11378
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 6
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0304/20100304409.pdf
[firstpage_image] =>[orig_patent_app_number] => 12472135
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/472135 | METHOD FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS AND A KIT FOR DETECTING PREMATURE SENESCENCE IN TUMOR CELLS | May 25, 2009 | Abandoned |
Array
(
[id] => 5551771
[patent_doc_number] => 20090285757
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-11-19
[patent_title] => 'METHODS OF TARGETING CELLS FOR DIAGNOSIS AND THERAPY'
[patent_app_type] => utility
[patent_app_number] => 12/467845
[patent_app_country] => US
[patent_app_date] => 2009-05-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 11
[patent_figures_cnt] => 11
[patent_no_of_words] => 15068
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0285/20090285757.pdf
[firstpage_image] =>[orig_patent_app_number] => 12467845
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/467845 | METHODS OF TARGETING CELLS FOR DIAGNOSIS AND THERAPY | May 17, 2009 | Abandoned |
Array
(
[id] => 5367019
[patent_doc_number] => 20090304578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-12-10
[patent_title] => 'Cancerous Disease Modifying Antibodies'
[patent_app_type] => utility
[patent_app_number] => 12/467036
[patent_app_country] => US
[patent_app_date] => 2009-05-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 13762
[patent_no_of_claims] => 47
[patent_no_of_ind_claims] => 12
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0304/20090304578.pdf
[firstpage_image] =>[orig_patent_app_number] => 12467036
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/467036 | Cancerous Disease Modifying Antibodies | May 14, 2009 | Abandoned |
Array
(
[id] => 6631635
[patent_doc_number] => 20100035339
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-02-11
[patent_title] => 'HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR'
[patent_app_type] => utility
[patent_app_number] => 12/433304
[patent_app_country] => US
[patent_app_date] => 2009-04-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 44925
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0035/20100035339.pdf
[firstpage_image] =>[orig_patent_app_number] => 12433304
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/433304 | HUMAN DIACYLGLYCEROL ACYLTRANSFERASE 2 (DGAT2) FAMILY MEMBERS AND USES THEREFOR | Apr 29, 2009 | Abandoned |